Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.
99% less funds holding
Funds holding: 247 → 2 (-245)
100% less funds holding in top 10
Funds holding in top 10: 21 → 0 (-21)
100% less capital invested
Capital invested by funds: $4.73B → $42.1K (-$4.73B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 239
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$428M |
| 2 |
BlackRock
New York
|
-$323M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$254M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$218M |
| 5 |
State Street
Boston,
Massachusetts
|
-$162M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
226
Steward Partners Investment Advisory
New York
| – | -$7K | -110 | Closed |
|
|
GEA
227
Glen Eagle Advisors
Kingston,
New Jersey
| – | -$3.95K | -58 | Closed |
|
228
US Bancorp
Minneapolis,
Minnesota
| – | -$4K | -54 | Closed |
|
|
KFI
229
Key Financial Inc
West Chester,
Pennsylvania
| – | -$3K | -50 | Closed |
|
|
NFSG
230
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$3K | -44 | Closed |
|
|
HWMA
231
Heritage Wealth Management (Arizona)
Phoenix,
Arizona
| – | -$2K | -31 | Closed |
|
|
QCG
232
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$2K | -28 | Closed |
|
|
AF
233
Allworth Financial
Folsom,
California
| – | -$2K | -24 | Closed |
|
|
EI
234
Ellevest Inc
New York
| – | -$1K | -19 | Closed |
|
|
S
235
SignatureFD
Atlanta,
Georgia
| – | -$1K | -18 | Closed |
|
236
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -12 | Closed |
|
GBT Hedge Fund Activity: Q4 2022 in Review
2 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.
Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.
- 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
- Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.
Based on aggregated 13F filings for Q4 2022.